Strang J, Darke S, Hall W, Farrell M, Ali R. Heroin overdose: the case for take-home naloxone. BMJ. 1996; 312: 1435–1436.
Strang J, Powis B, Best D, et al. Preventing opiate overdose fatalities with take-home naloxone: pre-launch study of possible impact and acceptability. Addiction. 1999; 94: 199–204.
Strang J. Take-home naloxone: the next steps. Comments on Strang et al’.s ‘Preventing opiate overdose fatalities with take-home naloxone: pre-launch study of possible impact and acceptability’. Addiction. 1999; 94: 206–207.
Best D, Gossop M, Man LH, Stillwell G, Coomber R, Strang J. Peer overdose resuscitation: multiple intervention strategies and time to response by drug users who witness overdose. Drug Alcohol Rev. 2002; 21: 269–274.
Strang J, Kelleher MJ, Best D, Mayet S, Manning V. Preventing heroin overdose deaths with emergency naloxone. Br Med J. 2006; 333: 614–615.
Strang J, Manning V, Mayet S, et al. Family carers and the prevention of heroin overdose deaths: unmet training need and overlooked intervention opportunity. Drugs Educ Prev Policy. 2008; 15: 211–218.
Darke S, Hall W. The distribution of naloxone to heroin users. Addiction. 1997; 92: 1195–1199.
Bird SM, Hutchinson SJ. Male drugs-related deaths in the fortnight after release from prison: Scotland, 1996–99. Addiction. 2003; 98: 185–190.
Seal KH, Downing M, Kral AH, et al. Attitudes about prescribing take-home naloxone to injection drug users for the management of heroin overdose: a survey of street-recruited injectors in the San Francisco Bay Area. J Urban Health. 2003; 80: 291–301.
Seal KH, Thawley R, Gee L, et al. Naloxone distribution and cardiopulmonary resuscitation training for injection drug users to prevent heroin overdose death. J Urban Health. 2005; 82: 303–311.
Tracy M, Piper TM, Ompad D, et al. Circumstances of witnessed drug overdose in New York City: implications for intervention. Drug Alcohol Depend. 2005; 79: 181–190.
Baca CT, Grant KJ. Take-home naloxone to reduce heroin death. Addiction. 2005; 100: 1823–1831.
Coffin PO, Galea S, Ahern J, Leon AC, Vlahov D, Tardiff K. Opiates, cocaine and alcohol combinations in accidental drug overdose deaths in New York City, 1990–98. Addiction. 2003; 98: 739–747.
Galea S, Worthington N, Piper TM, Nandi VV, Curtis M, Rosenthal DM. Provision of naloxone to injection drug users as an overdose prevention strategy: early evidence from a pilot study in New York City. Addict Behav. 2006; 31: 907–912.
Maxwell S, Bigg D, Stanczykiewicz K, Carlberg-Racich S. Prescribing naloxone to actively injecting heroin users: a program to reduce heroin overdose deaths. J Addict Dis. 2006; 25: 89–96.
Pollini RA, McCall L, Mehta SH, Celentano DD, Vlahov D, Strathdee SA. Response to overdose among injection drug users. Am J Prev Med. 2006; 31: 261–264.
Wright N, Oldham N, Francis K, Jones L. Homeless drug users’ awareness and risk perception of peer “Take Home Naloxone” use—a qualitative study. Subst Abuse Treat Prev Pol. 2006; 1: 28.
Lagu T, Anderson BJ, Stein M. Overdoses among friends: drug users are willing to administer naloxone to others. J Subst Abuse Treat. 2006; 30: 129–133.
Worthington N, Markham PT, Galea S, Rosenthal D. Opiate users’ knowledge about overdose prevention and naloxone in New York City: a focus group study. Harm Reduct J. 2006; 3: 19.
Sporer KA, Kral AH. Prescription naloxone: a novel approach to heroin overdose prevention. Ann Emerg Med. 2007; 49: 172–177.
Sherman S, Gann D, Scott G, Carlberg S, Bigg D, Heimer R. A qualitative study of overdose responses among Chicago IDUs. Harm Reduction J. 2008; 5: 2.
Dettmer K, Saunders B, Strang J. Take home naloxone and the prevention of deaths from opiate overdose: two pilot schemes. BMJ. 2001; 322: 895–896.
Bigg D. Data on take-home naloxone are unclear but not condemnatory. BMJ. 2002; 324: 678.
Galea S, Nandi A, Coffin PO, et al. Heroin and cocaine dependence and the risk of accidental non-fatal drug overdose. J Addict Dis. 2006; 25: 79–87.
Markham PT, Rudenstine S, Stancliff S, et al. Overdose prevention for injection drug users: lessons learned from naloxone training and distribution programs in New York City. Harm Reduct J. 2007; 4: 3.
Advisory Council on the Misuse of Drugs (ACMD). Drug-related deaths. London: Home Office. London, England: The Stationery Office; 2000.
Advisory Council on the Misuse of Drugs (ACMD). Consideration of naloxone. London: Home Office. London, England: The Stationery Office; 2012.
Edwards G, Strang J, Jaffe JH. Drugs alcohol tobacco: making the science and policy connections. Oxford, England: Oxford University Press; 1993.
Seaman SR, Brettle RP, Gore SM. Mortality from overdose among injecting drug users recently released from prison: database linkage study. BMJ. 1998; 316: 426–428.
Binswanger IA, Stern MF, Deyo RA, et al. Release from prison—a high risk of death for former inmates. N Engl J Med. 2007; 356: 157–165.
Farrell M, Marsden J. Acute risk of drug-related death among newly released prisoners in England and Wales. Addiction. 2008; 103: 251–255.
Darke S. [Commentary] From the can to the coffin: deaths among recently released prisoners. Addiction. 2008; 103: 256–257.
Merrall E, Kariminia A, Binswanger IA, Hobbs M, Farrell M, Marsden J, Hutchinson SJ, Bird SM. Meta-analysis of drug-related deaths soon after release from prison. Addiction. 2010; 105: 1545–1554.
Kariminia A, Butler T, Corben S, Levy M, Grant L, Kaldor J, et al. Extreme cause-specific mortality in a cohort of adult prisoners—1988 to 2002: a data-linkage study. Int J Epidemiology. 2007; 36: 310–316.
HM Government. Drugs: protecting families and communities. The 2008 Drug Strategy. Central Office of Information on behalf of HM Government, 2008. Report No.: CDSD9.
Darke S, Zador D. Fatal heroin ‘overdose’: a review. Addiction. 1996; 91: 1765–1772.
Hickman M, Madden P, Henry J, et al. Trends in drug overdose deaths in England and Wales 1993–98: methadone does not kill more people than heroin. (Erratum appears in Addiction 98: 1325–6). Addiction. 2003; 98: 419–425.
Davidson P, McLean R, Kral A, Gleghorn A, Edlin B, Moss A. Fatal heroin-related overdose in San Francisco, 1997–2000: a case for targeted intervention. J Urban Health. 2003; 80: 261–273.
Bryant WK, Galea S, Tracy M, Markham Piper T, Tardiff KJ, Vlahov D. Overdose deaths attributed to methadone and heroin in New York City, 1990–1998. Addiction. 2004; 99: 846–854.
Morgan OW, Johnson H, Rooney C, Seagroatt V, Griffiths C. Changes to the daily pattern of methadone-related deaths in England and Wales, 1993–2003. J Public Health. 2006; 28: 318–323.
Davoli M, Bargagli AM, Perucci CA, et al. Risk of fatal overdose during and after specialist drug treatment: the VEdeTTE study, a national multi-site prospective cohort study. Addiction. 2007; 102: 1954–1959.
Bird S. Shellacking over drug harms (response to Nutt, et al. Drug Harm in the UK). Lancet. 2010; 377: 552–553.
Powis B, Strang J, Griffiths P, et al. Self-reported overdose among injecting drug users in London: extent and nature of the problem. Addiction. 1999; 94: 471–478.
Strang J, Best D, Man LH, Noble A, Gossop M. Peer-initiated overdose resuscitation: fellow drug users could be mobilised to implement resuscitation. Int J Drug Policy. 2000; 11: 437–445.
Hickman M, Carrivick S, Paterson S, et al. London audit of drug-related overdose deaths: characteristics and typology, and implications for prevention and monitoring. Addiction. 2007; 102: 317–323.
Coffin PO, Tracy M, Bucciarelli A, Ompad D, Vlahov D, Galea S. Identifying injection drug users at risk of nonfatal overdose. Acad Emerg Med. 2007; 14: 616–623.
White JM, Irvine RJ. Mechanisms of fatal opioid overdose. Addiction. 1999; 94: 961–972.
Strang J. Sexual and injecting behaviors of prisoners: from disciplinary problem to public health conundrum. Crim Behav Ment Health. 1993; 3: 393–402.
Bird AG, Gore SM, Burns SM, Duggie JG. Study of infection with HIV and related risk factors in young offenders’ institution. BMJ. 1993; 307: 228–231.
Bird AG, Gore SM, Hutchinson SJ, Lewis SC, Cameron S, Burns S. Harm reduction measures and injecting inside prison versus mandatory drugs testing: results of a cross sectional anonymous questionnaire survey. The European Commission Network on HIV infection and hepatitis in prison. BMJ. 1997; 315: 21–24.
Maden A, Swinton M, Gunn J. A survey of pre-arrest drug use in sentenced prisoners. Addiction. 1992; 87: 27–33.
Strang J, Gossop M, Heuston J, Green J, Whiteley C, Maden A. Persistence of drug use during imprisonment: relationship of drug type, recency of use and severity of dependence to use of heroin, cocaine and amphetamine in prison. Addiction. 2006; 101: 1125–1132.
Fazel S, Bains P, Doll H. Substance abuse and dependence in prisoners: a systematic review. Addiction. 2006; 101: 181–191.
Rounds-Bryant JL, Baker L. Substance dependence and level of treatment need among recently-incarcerated prisoners. Am J Drug Alcohol Abuse. 2007; 33: 557–561.
Gore SM, Bird AG. Study size and documentation to detect injection-related hepatitis C in prison. QJM. 1998; 91(5): 353–357.
Mason D, Birmingham L, Grubin D. Substance use in remand prisoners: a consecutive case study. BMJ. 1997; 315: 18–21.
Brooke D, Taylor C, Gunn J, Maden A. Substance misusers remanded to prison-a treatment opportunity? Addiction. 1998; 93: 1851–1856.
Brooke D, Taylor C, Gunn J, Maden A. Substance misuse as a marker of vulnerability among male prisoners on remand. Br J Psychiatry. 2000; 177: 248–251.
Farrell M, Boys A, Singleton N, et al. Predictors of mental health service utilization in the 12 months before imprisonment: analysis of results from a national prisons survey. Aust N Z J Psychiatry. 2006; 40: 548–553.
Maden A, Swinton M, Gunn J. Women in prison and use of illicit drugs before arrest. BMJ. 1990; 301: 1133.
Gore SM, Bird GA, Burns S, Ross AJ, Goldberg D. Anonymous HIV surveillance with risk-factor elicitation: at Perth (for men) and Cornton Vale (for women) Prisons in Scotland. Int J STD AIDS. 1997; 8: 166–175.
Maden T, Swinton M, Gunn J. Psychiatric disorder in women serving a prison sentence. Br J Psychiatry. 1994; 164: 44–54.
Boys A, Farrell M, Bebbington P, et al. Drug use and initiation in prison: results from a national prison survey in England and Wales. Addiction. 2002; 97: 1551–1560.
Gore SM, Bird AG, Ross AJ. Prison rites: starting to inject inside. BMJ. 1995; 311: 1135–1136.
Lenton SR, Hargreaves KM. Should we conduct a trial of distributing naloxone to heroin users for peer administration to prevent fatal overdose? Med J Aust. 2000; 173: 260–263.
Mountain D. Big conclusions are drawn from little evidence. BMJ. 2001; 323: 934.
Darke S, Ross J, Hall W. Overdose among heroin users in Sydney, Australia: II. Responses to overdose. Addiction. 1996; 91: 413–417.
Darke S, Williamson A, Ross J, Teesson M. Non-fatal heroin overdose, treatment exposure and client characteristics: findings from the Australian Treatment Outcome Study (ATOS). Drug Alcohol Rev. 2005; 24: 425–432.
Coffin PO, Fuller C, Vadnai L, Blaney S, Galea S, Vlahov D. Preliminary evidence of health care provider support for naloxone prescription as overdose fatality prevention strategy in New York City. J Urban Health. 2003; 80: 288–290.
Gossop M, Griffiths P, Powis B, Williamson S, Strang J. Frequency of non-fatal heroin overdose: survey of heroin users recruited in non-clinical settings. BMJ. 1996; 313: 402.
McGregor C, Darke S, Ali R, Christie P. Experience of non-fatal overdose among heroin users in Adelaide, Australia: circumstances and risk perceptions. Addiction. 1998; 93: 701–711.
Bennett GA, Higgins DS. Accidental overdose among injecting drug users in Dorset, UK. Addiction. 1999; 94: 1179–1189.
Davidson PJ, Ochoa KC, Hahn JA, Evans JL, Moss AR. Witnessing heroin-related overdoses: the experiences of young injectors in San Francisco. Addiction. 2002; 97: 1511–1516.
Baca CT, Grant KJ. What heroin users tell us about overdose. J Addict Dis. 2007; 26: 63–68.
Best D, Gossop M, Man L-H, Finch E, Greenwood J, Strang J. Accidental and deliberate overdose among opiate addicts in methadone maintenance treatment: are deliberate overdoses systematically different? Drug Alcohol Rev. 2000; 19: 213–216.
Beswick T, Best D, Bearn J, et al. From salt injection to naloxone: accuracy and myths in peer resuscitation methods for opiate overdose. J Drug Issues. 2002; 32: 1103–1114.
Strang J, Manning V, Mayet S, Best D, Titherington E, Santana L. Preventing overdose death through overdose management training and provision of take-home naloxone to opiate users in treatment: prospective cohort study of impact on knowledge, attitudes and behavior. Addiction. 2008; 103: 1648–1657.
Wanger K, Brough L, Macmillan I, Goulding J, MacPhail I, Christenson J. Intravenous vs subcutaneous naloxone for out-of-hospital management of presumed opioid overdose. Acad Emerg Med. 1998; 5: 293–299.
Clarke SF, Dargan PI, Jones AL. Naloxone in opioid poisoning: walking the tightrope. Emerg Med J. 2005; 22: 612–616.
Vilke GM, Buchanan J, Dunford JV, Chan TC. Are heroin overdose deaths related to patient release after pre-hospital treatment with naloxone? Prehosp Emerg Care. 1999; 3: 183–186.
Vilke GM, Sloane C, Smith AM, Chan TC. Assessment for deaths in out-of-hospital heroin overdose patients treated with naloxone who refuse transport. Acad Emerg Med. 2003; 10: 893–896.
Strang J, Metrebian N, Lintzeris N, Potts L, Carnwarth T, Mayet S, et al. Heroin on trial: the RIOTT randomized trial of supervised injectable heroin and injectable methadone as treatment for chronic heroin addicts persistently failing in orthodox treatment. Lancet. 2010; 375: 1885–1895.
Mackie P, Morling J. Commissioning prison health: opportunities and challenges for creating a new prison public health system in Scotland. Public Health. 2009; 123: 434–437.
Brown CA, Lilford RJ. The stepped wedge trial design: a systematic review. BMC Med Res Methodol. 2006; 6: 54.
Hussey MA, Hughes JP. Design and analysis of stepped wedge cluster randomized trials. Contemp Clin Trials. 2007; 28: 182–191.
Strang J, Babor T, Caulkins J, Fischer B, Foxcroft D, Humphreys K. Drug policy and the public good: evidence for effective interventions. Lancet. 2012; 379: 71–83.
Reed J, Lyne M. The quality of health care in prison: results of a year’s programme of semi-structured inspections. BMJ. 1997; 315: 1420–1424.
Dolan K, Wodak AD, Hall WD. Methadone maintenance treatment reduces heroin injection in New South Wales prisons. Drug Alcohol Rev. 1998; 17: 153–158.
Dolan KA, Shearer J, MacDonald M, Mattick RP, Hall W, Wodak AD. A randomized controlled trial of methadone maintenance treatment versus wait list control in an Australian prison system. Drug Alcohol Depend. 2003; 72: 59–65.
Whitling NJ. New policy on methadone maintenance treatment in prisons established in Alberta. Can HIV AIDS Policy Law Rev. 2003; 8: 45–47.
Kinlock TW, Gordon MS, Schwartz RP, O’Grady K, Fitzgerald TT, Wilson M. A randomized clinical trial of methadone maintenance for prisoners: results at 1-month post-release. Drug Alcohol Depend. 2007; 91: 220–227.
Rich J, Boutwell A, Shield D, et al. Attitudes and practices regarding the use of methadone in US State and federal prisons. J Urban Health. 2005; 82: 411–419.
Merrall EL, Bird SM, Hutchinson SJ. A record-linkage study of drug-related death and suicide after hospital discharge among drug-treatment clients in Scotland, 1996–2006. Addiction. 2012. doi:10.1111/j.1360-0443.2012.04066